Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Axovant Sciences Ltd. (NASDAQ: AXON).

Full DD Report for AXON

You must become a subscriber to view this report.


Recent News from (NASDAQ: AXON)

Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder
Primary efficacy endpoint assessed by sleep laboratory video assessment was not met Axovant is discontinuing clinical development of nelotanserin  BASEL, Switzerland, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) a clinical-stage gene therapy company, toda...
Source: GlobeNewswire
Date: December, 10 2018 07:00
Axovant Sciences beats by $0.05
Axovant Sciences (NASDAQ: AXON ): Q2 GAAP EPS of -$0.28  beats by $0.05 . More news on: Axovant Sciences, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 07 2018 17:30
Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates
First patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s disease Expanded pipeline of gene therapies with in-licensing of AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy (OPMD) and collaboration agreement for five a...
Source: GlobeNewswire
Date: November, 07 2018 16:05
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson's Disease
Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, today announced dosing of the first patient ...
Source: GlobeNewswire
Date: October, 25 2018 02:00
Axovant to Present at Two Upcoming Investor Conferences
BASEL, Switzerland, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September 27, 2018 at 9:45 a.m. ET. Additionally, Dr. Cheru...
Source: GlobeNewswire
Date: September, 20 2018 07:00
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...
Source: SeekingAlpha
Date: September, 07 2018 07:32
Axovant to Present at Upcoming Investor Conferences
BASEL, Switzerland, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor conferences.   Dr Cheruvu will present a corporate overview at the H.C. Wainwright 20 ...
Source: GlobeNewswire
Date: August, 29 2018 07:00
Today's Research Reports on Stocks to Watch: Axovant Sciences and Gevo
NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Gevo and Axovant Sciences had something in common on Tuesday. Both stocks saw significant moves north despite any news nor catalyst. RDI Initiates Coverage on: Axovant Sciences Ltd. https://rdinvesting.com/news/?ticker=AXON Gevo, Inc....
Source: ACCESSWIRE IA
Date: August, 22 2018 08:00
FDA and NIH to loosen oversight of gene therapy development
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study...
Source: SeekingAlpha
Date: August, 16 2018 09:47
What Is Going On At Axovant Sciences?
On February 12, 2018, Axovant Sciences ( AXON ) issued a press release noting changes to the management team and Board of Directors. Dr David Hung retired as CEO and Dr Pavan Cheruvu took his place, among other changes. Three and a half months of radio silence followed. What broke the sile...
Source: SeekingAlpha
Date: August, 15 2018 09:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-082.302.212.402.20573,704
2018-05-171.241.231.241.19305,896
2017-06-2021.6323.1223.739921.315793,061
2017-06-1921.1821.5221.8921.01331,914
2017-06-1620.6121.0321.3520.12512,248

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-11131,919309,87142.5722Short
2018-12-10590,490941,51762.7169Short
2018-12-0747,003106,84743.9909Short
2018-12-06179,946268,06767.1272Short
2018-12-04102,751224,63245.7419Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AXON.


About Axovant Sciences Ltd. (NASDAQ: AXON)

Logo for Axovant Sciences Ltd. (NASDAQ: AXON)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $132,579,331 - 05/14/2018
  • Issue and Outstanding: 107,788,074 - 02/08/2018

 


Recent Filings from (NASDAQ: AXON)

Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: March, 14 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 09 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: January, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 21 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 06 2017
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: November, 29 2017
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: November, 17 2017

 

 


Daily Technical Chart for (NASDAQ: AXON)

Daily Technical Chart for (NASDAQ: AXON)


Stay tuned for daily updates and more on (NASDAQ: AXON)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AXON)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AXON is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AXON and does not buy, sell, or trade any shares of AXON. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/